Business
This episode contains the following;A look back at Japanese biotech that has not been able to push a single drug to phase 2 in 13 years, and an oil & gas company which pays their investor relations director over 700,000 $ or six times the average.Tickers & ReportsMuddy Waters on Peptidream (4587.JP)Culper Research on ProPetro (PUMP)Note: The IR salary of Sam Sledge is more like 6x than 7x just to be precise.